Introduction
============

The heart utilizes free fatty acids (FFAs) to generate a significant proportion of its energy source. Under normal conditions in the heart, circulating lipid is maintained through a regulated balance between cardiac lipid uptake and oxidation. During pathological situations, such as in metabolic disorders, fat levels exceed the storage capacity of adipocytes. The excessive circulating FFA levels underlie fatty acid infiltration of cardiomyocytes ([@B228]). Therefore, in metabolic disorders including obesity, type 2 diabetes (T2D) and insulin resistance, FFA levels increase to \>1 mM from normal levels (0.2--0.8 mM) ([@B5]). The excess amounts of FFAs are subsequently converted into triglycerides and stored as lipid droplets. The chronic accumulation of lipid droplets and/or lipid metabolic intermediates within the myocardium may directly disrupt cardiac function associated with lipotoxic cardiomyopathy ([@B215]). The expectation is that over time the constant and continuous metabolic stress is likely to lead to heart failure. Thus, metabolic-related studies that focus on understanding the progressive deterioration of myocardial structural and electrical integrity are needed. Investigations of molecular mechanisms that occur in the initial phase of the disease state are especially important.

In recent years, there have been studies that have supported this notion. For example, an elegant study conducted by Taegtmeyer and others ([@B203]), used both failing human hearts from diabetes and obesity patients, and hearts from ZDF rats with intramyocardial lipid deposition. It was demonstrated that myocardial lipid accumulation led to an upregulation of pathological markers of impaired fatty acid metabolism (peroxisome proliferator-activated receptor alpha, PPARα), contractility (myosin heavy chain beta, MHC-β), and inflammatory response (tumor necrosis factor alpha, TNF-α). Genetically manipulated mice, with altered cardiac-specific metabolic pathways (lipid transport and storage) display decreased mitochondrial biogenesis ([@B78]) and impaired diastolic function ([@B38]; [@B65]). We have also shown that high-fat diet induced obesity caused atrial electrical remodeling associated with vulnerability to atrial fibrillation (AF) ([@B14]).

Furthermore, fatty acid metabolism has been investigated as a contributing factor in the pathogenesis of lipotoxic cardiomyopathy and heart failure ([@B222]). These studies assessed the impact of altered expression of genes involved in regulation of FFA uptake and metabolism (acyl-CoA synthetase), FFA transport (FATP1) ([@B38]), and lipid utilization (adipose triglyceride lipase, ATGL) ([@B94]; [@B95]). For example, Goldberg's group previously showed that mice fed a normal diet but overexpressing cardiac-specific lipoprotein lipase (LpL), an enzyme that hydrolyzes circulating triglycerides and releases FFAs, displayed dilated hearts with left ventricular systolic dysfunction ([@B248]). Schaffer and others have also reported that mice overexpressing cardiac FATP1 developed cardiac phenotypes like those seen in T2D and obese animals ([@B38]). Collectively, these studies provide convincing evidence that cardiomyocyte-specific lipid deposition is critically associated with cardiac abnormalities in metabolic disorders.

Despite the clinical implications of lipid accumulation in the heart ([@B177]; [@B89]; [@B9]; [@B48]), the underlying molecular mechanisms are poorly understood. A major limitation could be due to the complexity associated with the involvement of multiple signaling pathways which include: (1) direct modulation of ion channel function by FFAs, and (2) FFA activation of the toll-like receptor (TLR) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) leading to secretion of pro-inflammatory cytokines ([@B99]) and subsequent cardiac electrical remodeling. Previous reports have demonstrated that FFAs increase inflammation ([@B145]), while genetic knockdown of TLR is protective in mice fed a high-fat diet rich in palmitate ([@B47]). Despite the clinical implications of these findings, there is a paucity of studies that address modulation of ion channels through activation of the SFFAs/TLR/NFκB/cytokine pathway in heart.

Here we review the recent developments regarding myocardial lipid accumulation as a mechanism contributing to cardiac ion channel dysfunction. We further discuss a role for pro-inflammatory cytokines, and more importantly interleukin-6 (IL-6), a dynamic and multifunctional cytokine with well-defined pro-inflammatory and anti-inflammatory functional characteristics ([@B214]; [@B155]; [@B124]; [@B219]). The knowledge that the immune system is an important component of dysregulated metabolic pathways is a key step to understanding the pathogenesis of heart failure in patients. We provide our viewpoint on whether targeting cytokine signaling pathways in the heart may be a different mechanism to treat arrhythmias. The possibility of this mechanism-based approach is strengthened by a recent report by Tyler's group ([@B134]). The investigators describe the feasibility of using non-invasive hyperpolarized magnetic resonance imaging with \[1-^13^C\]pyruvate as a marker of cytokine production. This non-invasive test will make it possible to screen obese and diabetic patients for early signs of heart failure.

Molecular Signaling Pathways of Cardiolipotoxicity That Promote Cardiac Inflammation
====================================================================================

Free-Fatty Acids
----------------

There is increasing evidence that dietary FFAs are a critical and independent predictor of metabolic disorders including insulin resistance, T2D and obesity ([@B113]; [@B173]), and related cardiac dysfunction ([@B87]; [@B201]; [@B165]; [@B14]; [@B11]). This association underscores the importance of studies that provide vigorous and comprehensive molecular insights into the structural determinants of the functional properties of FFA as well as FFA-activated signaling pathways in heart. FFAs are characterized by a straight chain of carbon atoms with both a carboxylic (COOH) and a methyl (CH~3~ or omega, ω) end ([@B186]) and are generally classified based upon the level of saturation on the carbon atoms. Accordingly, FFAs are classified into three main groups: (1) saturated fatty acids (SFAs) that do not contain double bonds (C16:0 and C18:0), (2) monounsaturated fatty acids (MUFAs), that contain only one double bond (C18:1), and (3) polyunsaturated fatty acids (PUFAs), that contain at least two double bonds ([@B98]). PUFAs, are divide into two classes namely: ω-3 and ω-6, based on the position of the first double bond relative to the ω end.

The anti-arrhythmic or cardioprotective effects of PUFAs, especially in patients with dyslipidemia, have been studied extensively ([@B187]; [@B196]; [@B198]; [@B254]). Billman and others have shown that the omega-3 PUFA eicosapentaenoic acid prevented ischemia-induced ventricular fibrillation in a dog model of sudden cardiac death ([@B23]), suggesting modulation by PUFAs of cardiomyocyte electrical activity ([@B26]; [@B247]; [@B25]; [@B126]; [@B158]). Some of the molecular mechanisms that may underlie the cardioprotective effects of PUFAs include effects on channel gating ([@B57]) and membrane properties (or electrostatics) ([@B29]; [@B28]; [@B136]), and have been comprehensively reviewed elsewhere ([@B127]).

If the relative composition of FFA content in the heart can influence inflammatory responses, and affect cardiac dysfunction, then dietary PUFAs may prevent pathological levels of pro-inflammatory cytokines ([@B241]; [@B166]), and cardiac dysfunction in patients with metabolic disorders. Moreover, PUFAs have been shown to decrease secretion of TNF-α, IL-1β, and IL-6 through a pathway involving M2 anti-inflammatory macrophages ([@B146]). However, the molecular partners involved are unknown, and therefore the mechanisms are poorly understood. Future studies are needed to investigate the differences between inflammatory pathways activated by the cardioprotective PUFAs and the generally more damaging SFFAs (M1 anti-inflammatory macrophages) ([@B146]), and whether further differences would be seen with acute versus chronic activation of these pathways.

Saturated long chain FFAs, particularly palmitic acid (PA, 16:0), which is one of the predominant FFAs in epicardial fat ([@B102]), are considered to be a more prominent contributor to systemic lipotoxicity compared to long chain monounsaturated FFAs such as oleic acid (OA) ([@B227]; [@B138]; [@B113]). Previously we demonstrated that exogenous application of PA conjugated with bovine serum albumin (BSA) shortened atrial action potential (AP) duration (APD), measured in guinea pig atrial myocytes, while OA prolonged atrial APD ([@B14]). Similarly, Anumonwo's group found that a short-term exposure to the saturated stearic acid caused both structural and electrical remodeling of atrial myocytes isolated from sheep ([@B165]), consistent with pathological cardiomyocyte remodeling. Notably, the American Heart Association (AHA) has reported a significant association between dietary FFA and the pathogenesis of a variety of cardiovascular diseases ([@B117]). The 2013 AHA/American College of Cardiology (ACC) Guideline on Lifestyle Management to Reduce Cardiovascular Risk recommends that patients with elevated low-density lipoprotein (LDL)- cholesterol decrease the intake of dietary saturated fat to 5--6% of the total daily caloric intake ([@B56]).

Despite these guidelines, diet-related diseases such as obesity, T2D and insulin resistance and associated cardiac dysfunction ([@B113]; [@B16]; [@B226]; [@B191]) are still widespread. This suggests that other mechanisms or pathways are involved, such as inflammation and cytokine release, which are activated by SFFAs. Accordingly, the anti-inflammatory effects of current therapeutic interventions (statins or APOA1) ([@B79]; [@B202]) are promising and are likely to inform future studies.

The mechanisms of FFA toxicity are complex, involving multiple combinations of distinct signaling pathways ([@B186]; [@B173]), suggesting the need to expand our understanding of how the interplay of these pathways lead to a diseased state. In this review we provide insights on the relatively unexplored interplay between cardiac lipotoxicity (mediated by SFFAs) and inflammatory pathways (macrophages, toll-like receptors, proinflammatory cytokines) that impair ion channel function, leading to cardiac electrical activity and conduction abnormalities. Our expectation is that understanding the cardiac-specific inflammatory pathways may facilitate the design and rational development of effective therapeutic interventions. These mechanisms are discussed below.

Saturated Free-Fatty Acids and Inflammation
-------------------------------------------

Over the past 40 years we have been able to establish a role for SFFAs in inflammation ([@B2]; [@B31]; [@B32]; [@B84]; [@B97]; [@B238]; [@B195]; [@B85]). Cardiac or systemic inflammation (or dysregulation of the innate immune system) is thought to be a function of the body's non-specific response to injury ([@B176]). In obese and diabetic patients, the increased rates of infection and poor wound healing have been associated with immune cell dysfunction ([@B108]; [@B62]; [@B70]; [@B107]; [@B229]). Importantly, macrophages are associated with heightened immune responses to infectious pathogens and tissue damage in diabetes ([@B156]; [@B157]; [@B46]; [@B140]) and obesity ([@B143]; [@B185]; [@B50]).

Given that FFAs are important adipocyte-derived mediators of macrophage related inflammation ([@B210]) and macrophages can infiltrate and/or directly couple with cardiomyocytes (Figure [1](#F1){ref-type="fig"}; [@B100]; [@B189]), then macrophages may be important mediators of SFFA effects on cardiac electrical remodeling ([@B236], [@B237]). Distinct voltage-dependent *K* channels (VGKC) including ether-á-go-go related gene 1 (ERG1), ([@B53]), inward rectifier ([@B231]; [@B159]), and shaker-related or K~v~1.3 ([@B231]; [@B172]; [@B233]) are found in macrophages. In addition to their role in controlling cardiac repolarization and resting membrane potential ([@B80]; [@B104]), VGKC are also involved in macrophage functions (activation, migration, proliferation) ([@B231]). Because altered functions of macrophages could have important implications for proinflammatory cytokine release and arrhythmias, future studies will have to characterize the biophysical effects of VGKC localized to macrophages more precisely and determine whether impaired cardiac electrical activity includes altered macrophage ion channel function. For example, does the modulatory signaling pathways (including protein kinases, protein phosphatases, trafficking, anchoring proteins, and posttranslational modifications) that regulate cardiac VGKC subunit expression also regulate these channels in macrophages? These studies are a prerequisite for development of new therapeutics which target inflammatory pathways in lipotoxic-related disorders.

![Functional crosstalk between macrophages and cardiomyocytes. The schematic shows functional coupling between macrophages and cardiomyocytes through gap junctional channels. Small molecules including ATP are exchanged between cells with implications for inflammatory response. Macrophages have been shown to express ion channels that are similar to depolarizing (*I~Ca~*, *I~Na~*) and repolarizing mechanisms in heart (*I~Kr~*, *I~Ks~*, and *I*~*K*1~). Previously Van Wagoner and others ([@B45]), reported functional expression of Ca~v~1.2 channels in macrophages, that could be blocked by known Ca channel blockers (amlodipine and verapamil), but were voltage-independent. Macrophages also express I~HERG~-like currents, that are unrelated to cardiac *I~Kr~* ([@B174]; [@B259]), and inwardly rectifying K channels ([@B159]; [@B109]). What role, if any do the expression of these channels play in mediating the effects of SFFAs on cardiac electrical activity? Despite the lack of clarity, macrophages are likely to influence cardiac electrical function to help maintain homeostatic control. This influence could be via direct (TL4R-cytokine release) or indirect (ATP-P2X7R) signaling pathways. Distinguishing between multiple pathways is likely to further illuminate the role of cardiac macrophages in inflammation and the pathogenesis of lipotoxic cardiomyopathy.](fphys-09-01866-g001){#F1}

SFFAs have been shown to stimulate an inflammatory response by acting on TLRs present on macrophages (Figure [1](#F1){ref-type="fig"}). TLRs are pattern recognition receptors that play an important role in the body's innate immune response ([@B217]; [@B195]). Thus, if inflammation is a hallmark of lipotoxicity ([@B60]; [@B184]), then the role of SFFAs as an activator of TLRs must be understood because they initiate inflammation.

Saturated Free-Fatty Acids and Toll-Like Receptor Signaling
-----------------------------------------------------------

Structurally, TLRs are characterized by three distinct domains, namely: (1) an extracellular leucine-rich repeat (LRR) domain, which is required and necessary for ligand binding and the recognition of pathogen-associated molecular patterns (PAMPs); (2) a transmembrane domain important for receptor localization to the surface (TLR1, TLR2, TLR4, TLR5, TLR6) and intracellular membranes (TLR3, TLR7, TLR8, TLR9); 3) a cytoplasmic conserved toll/interleukin-1 receptor (TIR) domain, which plays a role in the activation of NF-κB, and cytokine secretion (Figure [2](#F2){ref-type="fig"}; [@B71]). TLR2 and TLR4 have been widely studied and have both been shown to play a role in the pathogenesis of lipid disorders like atherosclerotic cardiovascular disease ([@B42]), insulin resistance ([@B49]; [@B244]; [@B115]; [@B52]), and obesity ([@B114]; [@B76]).

![Cardiac and macrophage inflammatory pathways. In metabolic disorders, enlargement of adipocytes contributes to the activation of macrophages and release of SFFAs through lipolysis ([@B239]). The exposure of cells to increased levels of these inflammatory molecules leads to the activation of inflammatory pathways. The cartoon representation shows the activation of the TLR signaling pathways (MyD88-dependent and -independent), by SFFAs in both macrophages and cardiomyocytes. Infiltration of cardiomyocytes by M1 pro-inflammatory macrophages may lead to cardiac electrical dysfunction, cause arrythmias leading to cardiomyopathies of metabolic disorders. The MyD88-dependent pathway involves sequentially, activation of IRAK4, phosphorylation of IRAK1/2, and TRAF6, followed by activation of IKK and NF-κB, and the subsequent production or secretion of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β). The MyD88-independent pathway also involves the secretion of pro-inflammatory cytokines through activation of TRAF6 by TRAM/TRIF. SFFA, Saturated free-fatty acid; TLR, Toll-like receptor; MD-2, myeloid differentiation protein-2; TIR, Toll/interleukin-1 receptor; TRIF, TIR-domain-containing adapter-inducing interferon-β; TRAM, TRIF-related adapter molecule; TRAF, tumor necrosis factor receptor-associated factor; IRAK, interleukin-1 receptor-associated kinase; TAK, transforming growth factor β activated kinase; IKK, inhibitory kappa B alpha kinase; NF-κB, nuclear factor-kappa B; Ub, ubiquitin.](fphys-09-01866-g002){#F2}

SFFAs have been shown to promote both TLR4-dependent and TLR2-dependent signaling in multiple cell models. For example, [@B129], [@B131]), using RAW 264.7 macrophages, demonstrated that the saturated lauric acid (C12:0), signaled *via*: (1) TLR4-myeloid differentiation primary response 88 (MyD88) to activate NF-κB; (2) TLR4-Toll-IL-1 receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF), leading to the activation of interferon-stimulated regulatory element. Furthermore, endogenous SFFAs released from adipocytes have also been shown to activate co-cultured macrophages *via* TLR4 ([@B211]), demonstrating an important crosstalk in adipose tissue, with implications for lipotoxicity and cardiac electrical remodeling. Similarly, TLR2 has been shown to mediate palmitate-induced insulin resistance in C2C12 myoblasts ([@B200]). Endothelial overexpression of TLR2 led to early development of atherosclerotic processes in the aorta of LDLr^-/-^ mice ([@B160]), while the downregulation of TLR2 protected against atherosclerosis in LDLr^-/-^ mice ([@B161]). Others have also shown similar effects of TLR2-deficiency in apoE^-/-^ mice ([@B141]; [@B148]). Reduced TLR4 expression and function protected against insulin resistance in a mouse model of systemic lipid infusion ([@B206]), demonstrating a role for TLRs in lipotoxic disorders ([@B20]; [@B204]). Flier and colleagues also found that female C57BL/6 mice lacking TLR4 and fed a high fat diet developed increased obesity, but are partially protected from insulin resistance through a mechanism involving reduced inflammatory gene expression (including IL-6) ([@B206]).

T2 diabetic mice with mutated TLR4 prevented endothelial cell dysfunction, hyperglycemia and hypertension when compared with wild-type. These effects were largely due to suppression of oxidative stress signaling molecules nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 and 4 ([@B135]). Furthermore, mice lacking either TLR4 or its downstream adapter protein MyD88 are protected against atherosclerosis ([@B24]; [@B154]; [@B51]). In agreement, humans with TLR4 mutations, which lead to reduced receptor signaling and depressed inflammatory response, are also less susceptible to atherosclerosis ([@B12]; [@B112]; [@B137]). Schwartz's group ([@B114]) also found that thoracic aortic samples from TLR4 knockout mice (TLR4^-/-^) fed a high-fat diet did not develop vascular inflammation or insulin resistance.

TLR4 are also expressed in normal myocardium ([@B225]), suggesting that it may play a role in cardiac function. Moreover, increased TLR4 expression has been reported in failing myocardium ([@B68]), and isolated cardiomyocytes from humans and animal models of different cardiomyopathies ([@B44]; [@B18]; [@B139]), including myocarditis ([@B221]). These findings provide strong hints that blocking TLR4 may be a promising cardioprotective target in patients. Whether and how effective modulation of the TLR4 pathway is as a therapeutic target is yet to be determined.

NF-κB Activation Signaling Pathways
-----------------------------------

Activated TLR4 and myeloid differentiation protein-2 (MD-2) signals through both the MyD88-dependent and MyD88-independent pathways (Figure [2](#F2){ref-type="fig"}; [@B130]; [@B73]). The MyD88-dependent pathway is initially triggered by the recruitment of the TIR domain containing adaptor protein (or TIRAP), an adaptor between the TIR domain of TLR4 and MyD88 ([@B190]). This is followed by activation of the interleukin-1 receptor-associated kinase (IRAK) 4 family of protein kinases which induces IRAK1/2 phosphorylation and the subsequent phosphorylation of TNF Receptor Associated Factor 6 (TRAF6) ([@B232]).

However, with the MyD88-independent pathway, the TLR4 pathway is activated through a TIR-containing adapter molecule 1 (TRIF)-related adaptor molecule TRAM. This allows the recruitment of TRIF and subsequent activation of TRAF6 (Figure [2](#F2){ref-type="fig"}). TRAF6, either directly, or *via* thylakoid arabidopsis kinase (TAK) 1, stimulates the inhibitor of nuclear factor-κB kinase (IKK) complex, which promotes phosphorylation of the inhibitor of NF-κB (IkB). In the resting state of a cell, IkB exists in a complex with NF-κB, which limits its spatial localization to cytosol. Phosphorylated IkB is ubiquitinated, dissociates from NF-κB, and is then subjected to proteasomal degradation. Free NF-κB (p50/p65 heterodimer) translocate to the nucleus and binds to κB sites in the promoter regions of genes involved in the secretion of inflammatory cytokines which includes TNF-α and IL-6 ([@B252]). Furthermore, the p50/p65 heterodimer may undergo a series of cellular protein modifications including phosphorylation, acetylation, and methylation with implications for a finely-tuned regulation of transcriptional activity of pro-inflammatory cytokines. Moreover, NF-κB transcriptional activity may also be regulated by secreted pro-inflammatory cytokines through a positive and/or negative feedback mechanism depending on the pathological state of the cell.

NF-κB-mediated cytokine release and inflammation may also be augmented through adenosine triphosphate (ATP) *via* purinergic signaling (Figure [1](#F1){ref-type="fig"}; [@B54]; [@B128]). In pathological conditions, ATP from cells pass through hemichannels to activate purinergic receptors, leading to an amplification of inflammation ([@B153]). Moreover inhibition of the ATP receptor P2X7 prevented cardiac dysfunction in a mouse model of acute myocardial infarction ([@B153]) and LPS-primed naive rats ([@B251]). P2X7 deficiency inhibited inflammasome activation and reduced atherosclerosis in P2X7^-/-^ mice ([@B207]). Therefore, activation of connexins and P2X7 receptors (P2X7R) signaling pathways represent emerging targets that can be explored in lipotoxic cardiomyopathies.

NF-κB and Cardiomyocyte Remodeling
----------------------------------

The role of NF-κB as a key transcription factor critical for regulation of cardiac inflammatory signaling pathways strongly suggests its involvement in cardiac remodeling leading to pathogenesis of heart failure ([@B258]; [@B194]; [@B197]). Previous reports have shown that NF-κB is activated in the failing human heart ([@B245]; [@B83]; [@B111]). Further, *in vitro* studies have also demonstrated that activation of NF-κB plays a role in hypertrophic growth of primary rat neonatal ventricular cardiomyocytes in response to angiotensin II, phenylephrine, and endothelin-1 ([@B181]). Recent studies have also demonstrated that NF-κB plays a partial role in the depression of the fast transient outward K current (*I~to,f~*) caused by chronic β-adrenergic receptor stimulation in cultured neonatal rat ventricular myocytes ([@B170], [@B169]). In these studies NF-κB effects were attributed to a downregulation of the pore-forming (K~v~4.3) and regulatory/auxiliary (KChIP2) subunits of *I~to,f~* ([@B170]). The functional consequence of NF-κB modulation may be due to transmural changes in *I~to,f~* in the ventricles and possibly the atria. These effects further highlight an emerging role for NF-κB as a substrate for cardiac dysfunction in lipotoxicity.

In a study by Kawamura and others, the blockade of NF-κB did not ameliorate myocardial inflammation, but significantly improved cardiac function and survival in a transgenic mice model with cardiac overexpression of TNF-α ([@B111]). Recently, a similar mechanism has been proposed for TRAF1, an inhibitory adapter of TLRs ([@B10]). It was found that downregulation of macrophage-resident TRAF1 induced increased expression of inflammatory genes and protected against metabolic dysfunction in mice. Therefore, it is possible that activation of the non-canonical NF-κB/TRAF1 pathway ([@B39]), may at least, in part, explain the effects of TNF-α described by Sunagawa' group ([@B111]).

The studies of Wolf and others also showed a convincing correlation between higher TRAF1 expression, body mass index, and fasting plasma lipid in patients with severe metabolic syndrome ([@B10]). Albeit interesting, the implications of these findings on cardiac function were not investigated. To reconcile existing knowledge of the relationship between metabolic disorders, inflammation and heart failure, we will need additional studies related to the spatial and temporal effects of TRAF1, inflammatory responses and effects on cardiac remodeling.

Nonetheless, we speculate that NF-κB activation may contribute to cardiac dysfunction independent of macrophage-related inflammation. Therefore, blockade of NF-κB leading to cardiac electrical remodeling may be a novel therapeutic strategy for cardiac diseases worth investigating. However, little is known about the effects of NF-κB inhibition in patients with metabolic disorders or any animal models of cardiac lipotoxicity and metabolic disorders including T2D, insulin resistance, and cardiac inflammation.

Saturated Free-Fatty Acid, NF-κB, and Proinflammatory Cytokines
---------------------------------------------------------------

A major signaling pathway for SFFA-mediated inflammatory response and cardiac electrical dysfunction may involve the following steps: (1) infiltration of cardiac macrophages into cardiomyocytes (2) increased functional expression and activation of TLR; (3) activation of NF-κB; (4) altered secretion of pro-inflammatory cytokines; and (4) ion channel remodeling (Figure [3](#F3){ref-type="fig"}). Recently the significance of this pathway was demonstrated in a LIPGENE cohort study ([@B41]), wherein NF-κB was found to regulate TNF-α release during postprandial period ([@B132]). Because the activation of this pathway may also depend on the amount and type of dietary fat, the potential of this pathway as an intervention strategy in overweight and obese patients with cardiac dysfunction deserves further investigation.

![Cartoon depiction illustrating potential saturated free-fatty acid mechanisms that may underlie arrhythmogenic events. High-fat diet induce elevations of saturated free-fatty acids (SFFAs) leading to increased expression of proinflammatory cytokines in macrophages. Cardiac macrophages sense high concentrations of SFFAs through the toll-like receptor 2 (TLR2) and/or toll-like receptor 4 (TLR4) which induces expression of inflammatory target genes including tumor necrosis factor (TNF)-α and interleukin-6 (IL-6), by regulating the activities of nuclear factor-κB (NF-κB) ([@B252]). SFFAs also induce interleukin-1β secretion via the NLRP3 inflammasome in macrophages, which is independent of the TLR4 pathway ([@B92]). Hemichannels control the exchange of small molecules including ATP ([@B242]). The released ATP binds to the cell-surface purinergic receptors P2X7R, and can control inflammation by regulating the release of pro-inflammatory cytokines (including IL-1β) ([@B77]). There is a paucity of lipid studies involving the IL-6 signaling pathway, and therefore the molecular mechanisms of IL-6 modulation of cardiac function is poorly understood. In cardiomyocytes, IL-6 mediates its effect through its classical pathway. IL-6 binds to the glycoprotein 80 transmembrane IL-6 receptor (IL-6R) ([@B249]), which leads to dimerization and activation of the signal transducing protein of glycoprotein 130 (gp130) and its downstream effector signaling molecules Janus kinase (JAK) 2/4 ([@B103]; [@B91]; [@B55]). We hypothesize that SFFA mediated cardiac electrical remodeling that increase vulnerability to arrythmias may occur through SFFAs/TLR/NF-kB-IL-6 mediated altered gene and protein expression of ion channel subunits, trafficking and/or gating defects. Distinguishing among these signaling pathways is likely to provide mechanistic insights that will influence considerations of anti-cytokine therapy for the management of metabolic disorders and arrythmias. The black ? indicates that whether or how activation of JAK2/4 leads to remodeling of ion channel molecular partners is poorly understood. The black? (associated with the purple arrows), represents an unresolved role for IL-6 modulation of major cardiac ion channels (*I~Ca~*, *I~Na~*, *I~Kr~*, and *I~Ks~*) in lipotoxicity and pathogenesis of arrhythmias including long QT syndrome (LQTS) and atrial fibrillation (AF).](fphys-09-01866-g003){#F3}

The TNF-α signaling pathway and its role in cardiac ion channel remodeling leading to cardiac dysfunction in animal models has been extensively studied ([@B142]; [@B235]; [@B88]; [@B110]; [@B175]; [@B61]; [@B81]). However, the functional consequence of the relative contribution of each one of the steps (SFFAs/TLR4/NF-κB) involved in TNF-α production and its subsequent regulation of cardiac function in relevant animal models of cardiac lipotoxicity is poorly understood. In contrast, it is known that the stimulatory effects of distinct SFFAs (lauric, palmitic and stearic acids) cause increased IL-6 functional expression in macrophages *via* TLR4 activation ([@B206]). Despite the role of IL-6 as a cardiovascular risk indicator ([@B124]), its function as modulator of cardiac electrical remodeling with implications for the pathogenesis of arrythmias is only beginning to be understood. In this review, we focus on the pathophysiology of the IL-6 signaling pathway and how its modulation may reveal crucial insights that will inform future lipid studies (Table [1](#T1){ref-type="table"}).

###### 

Correlation between IL-6, cardiac ion channel expression, and contractile function in arrhythmias.

  IL-6                           Cardiomyopathy                                   Model                                                                Ion channel and cardiomyocyte contractile function   Reference
  ------------------------------ ------------------------------------------------ -------------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  ↑                              1\. LQTS, 2. Ventricular arrythmias              Human                                                                NR                                                   [@B209]; [@B121], [@B125]
  1000 U/ml (5 min)              NR                                               Adult female guinea pig ventricular myocytes                         ↓*I~Ca~*, ?*I~Na~*, ?*I~Kr~*, ?*I~Ks~*               [@B212]
                                                                                                                                                       ↓contractility                                       
                                                                                                                                                       ↓ \[Ca^2+^\]~i~ transient                            
  400 pg/ml (1--3 h)             NR                                               Adult Rat (SD), ventricular myocytes.                                ↔ Cardiac contraction                                [@B147]
  10 ng/ml (2--24 h)             NR                                               Adult Rat (SD), ventricular myocytes                                 Negative inotropy                                    [@B253]
                                                                                                                                                       ↓ Cell shortening                                    
                                                                                                                                                       ↔*I~Ca~*, ?*I~Na~*, ?*I~Kr~*, ?*I~Ks~*               
                                                                                                                                                       ↓SR Ca content                                       
                                                                                                                                                       ↓Phosphorylation of Phospholamban                    
                                                                                                                                                       ↓SR Ca uptake                                        
                                                                                                                                                       ↓ Postrest potentiation and caffeine response        
  50 Units/ml (6 h)              NR                                               Rat neonatal (1--2 day old; Wistar), cultured ventricular myocytes   ↓ SERCA mRNA                                         [@B218]
  10 ng/ml (48 h)                NR                                               Rat neonatal (1--2 day old), cultured ventricular myocytes           ↓ SERCA2 mRNA                                        [@B234]
                                                                                                                                                       ↓ SERCA2 protein                                     
  20 ng/ml (20--40 min)          NR                                               Mice ventricular myocytes                                            ↑ *I~Ca,L~*, ?*I~Na~*, ?*I~Kr~*, ?*I~Ks~*            [@B86]
                                                                                                                                                       ↑ \[Ca^2+^\]~i~ transient                            
                                                                                                                                                       ↑ APD                                                
  1000 U/ml (30 min)             NR                                               Chick embryo cultured ventricular myocytes                           Negative inotropy                                    [@B116]
                                                                                                                                                       ↓Peak systolic \[Ca^2+^\]~i~                         
                                                                                                                                                       ↓Cell contraction                                    
  0.5--3000 ng/ml (10--30 min)   NR                                               Rat neonatal (2 day-old, Lewis) cultured ventricular myocytes        ↔ Cell shortening                                    [@B118]
  0.1--3 ng/ml (2--5 min)        NR                                               Hamster papillary muscle                                             Negative inotropy                                    [@B64], [@B63]
  ↑                              1\. AF                                           Human                                                                NR                                                   [@B40]; [@B152]; [@B178]; [@B27]; [@B72]; [@B75]; [@B223]; [@B151], [@B150]; [@B34]; [@B93]; [@B133]; [@B182]; [@B36]; [@B246]; [@B17]; [@B180]
                                 2\. Atrial flutter                                                                                                                                                         
                                 3\. Atrioventricular nodal reentry tachycardia                                                                                                                             
  0.1--3 ng/ml (2--5 min)        NR                                               Human pectinate muscle (Atria)                                       NR                                                   [@B63]
  ↑                              AF                                               Mice                                                                 NR                                                   [@B167]
                                                                                                                                                                                                            

↑, increased; ↓, decreased; ↔, no change; NR, not reported; SD, Sprague Dawley; WR, Wistar Rats.

Molecular Mechanisms of Interleukin-6 Signaling
-----------------------------------------------

IL-6 is a pleiotropic cytokine that is involved in a variety of biological effects that occur in cells of the immune system and also cardiomyocytes in response to injury ([@B7]; [@B250]). IL-6 mediates its effects either through its membrane-bound receptor, IL-6R alpha (α) subunit (classical signaling) or the soluble receptor (sIL-6R) ([@B216]; [@B66]), in complex with the signal transduction protein glycoprotein 130 (gp130) leading to the activation of the janus kinase (JAK)-related signaling pathways ([@B3], [@B4]; [@B163]; [@B216]; Figure [3](#F3){ref-type="fig"}).

Interleukin-6 Signaling and Propensity for Cardiac Arrhythmias
--------------------------------------------------------------

Cardiac arrhythmias are irregular variations from the normal cardiac sinus rhythm due to conduction abnormalities, or electrical impulses in the heart. It is well established that the abnormal electrical activity that predispose to arrhythmias is commonly due to dysfunction and/or structural disruption of the electrical conduction system of the heart and can be classified based on their pathogenesis. In particular, the underlying molecular mechanisms of IL-6 in the pathogenesis of ventricular and supraventricular arrhythmias are poorly understood. In this review we highlight current reports of IL-6 involvement in the pathogenesis of cardiac dysfunctions associated with increased vulnerability to fatal ventricular arrhythmias (long QT syndrome or LQTS) ([@B199]; [@B21]) or increased morbidity (atrial fibrillation or AF) and mortality (Table [1](#T1){ref-type="table"}). Our hope is that studies that distinguish between the molecular mechanisms of IL-6 contribution to LQTS and AF may reveal important mechanistic insights that will inform targeted therapeutic interventions that will be beneficial to all patients and help improve quality of life.

### Interleukin-6 and Long QT Syndrome

Previous studies have shown that circulating IL-6 levels are elevated in patients with autoimmune diseases ([@B1]; [@B119],[@B123], [@B124]) and are associated with the prolongation of corrected QT (QT~c~) or LQTS, a serious condition which increases vulnerability to fatal arrhythmias including *Torsades de Pointes* (*TdP*). These results were obtained by accumulating data from patients with myo/endocarditis ([@B224]; [@B122]) and systemic autoimmune diseases, particularly rheumatoid arthritis ([@B120], [@B124]; [@B1]) and connective tissue disease ([@B123]). There have also been reports of an association between elevated serum IL-6 concentrations and increased susceptibility to spontaneous ventricular tachyarrhythmia in patients with coronary artery disease ([@B209]). IL-6R expression is also upregulated in heart failure and therefore underscores an additional therapeutic role of IL-6R blockers in lipotoxic cardiomyopathies.

### Interleukin-6 and Atrial Fibrillation

Altered IL-6 functional expression is also a common feature of supraventricular arrythmias including AF ([@B151]; [@B168]), leading to higher risks of death and cardiovascular events in AF patients ([@B17]). Moreover, increased IL-6 levels have been attributed to persistent inflammation in atrial myocardium ([@B208]; [@B6]; [@B168]) and further supports the idea of an important functional link to supraventricular arrhythmias. Short-term (2 weeks) administration of the TLR4 agonist, LPS, induced NF-κB activation, increased IL-6 concentration (in plasma and right atrium), and increased vulnerability to AF in a canine model of systemic inflammation. The intimate structural relationship between SFFAs and LPS ([@B101]) would imply that similar mechanisms may underlie vulnerability to arrhythmogenic events mediated by SFFAs. These mechanisms warrant further analysis in cardiomyocytes and animal models.

Similar to LPS, SFFA activation of TLR4 increases circulating IL-6 levels in macrophages ([@B30]; [@B33]). Therefore, considering the idea of reported functional expression of TLR4 in cardiomyocytes ([@B68]; [@B19]; [@B256]; [@B37]; [@B105]; [@B106]) and the notion that cardiomyocytes secrete IL-6 ([@B7]; [@B147]), it will also be important to determine the temporal and relative contribution of these distinct pathways to impaired cardiac dysfunction mediated by the direct effects of SFFAs on cardiac function ([@B87]; [@B165]; [@B14]). The data is likely to reveal new targets that may be relevant to therapeutic responses in patients with metabolic disorders. This can be easily advanced by lipid studies in relevant animal and translational models of AF progression.

The growing evidence of a critical link between inflammation and arrhythmias provide strong initial clues as to the potential effects of SFFAs on ion channels through inflammatory cytokine signaling pathways leading to altered APD and QT~c~ interval. Therefore, it would be interesting to delineate the functional interplay among individual steps in the SFFAs/TLR4/NF-κB/cytokine pathway leading to ion channel remodeling.

Ion Channels and Cardiomyocyte Electrical Activity
--------------------------------------------------

The electrical activity of the human heart is controlled by the coordinated action of ion channels localized to distinct compartments (surface sarcolemma, t-tubular system, intercalated disk), within the myocardium. The temporal and biophysical properties of individual ionic channels allow the exchange of ions between distinct compartments and are responsible for generation of an AP in individual cardiomyocytes. The normal cardiac AP is defined by 5 distinct phases, namely: phase 0 or phase of rapid depolarization, due to a large inward Na current, *I~Na~* followed by currents due to voltage-gated L-type Ca (*I~Ca,L~*) and the sodium-calcium exchanger (*I~NCX~*) channels ([@B22]); phase 1 or phase of early repolarization controlled by the transient outward K current, *I~to~*; phase 2 or plateau phase accomplished by a balance between the depolarizing Ca current (*I~Ca,L~*) and the repolarizing rapidly (*I~Kr~*) and slowly (*I~Ks~*) activating component of the delayed rectifier K currents. The atria specific ultra-rapidly (*I~Kur~*) activating delayed rectifier K current controls repolarization ([@B220]) and underlies the triangular signature of the atrial AP ([@B67]); phase 3 (or phase of final repolarization) represents the inactivation of *I~Ca,L~* and is therefore predominantly regulated by the delayed rectifier K currents and the inwardly rectifying K current (*I*~*K*1~) ([@B230]). While extensive reviews about the pathophysiology of major cardiac ionic channels have recently been published ([@B13]; [@B43]; [@B90]; [@B183]), the importance of ion channel function to normal cardiac rhythm is exemplified in a variety of inherited and acquired pathological conditions. For example, in LQTS decreases in outward currents ([@B15]; [@B179]) or increases in depolarizing mechanisms ([@B240]; [@B69]; [@B35]; [@B96]), predispose to fatal ventricular arrhythmias (such as *TdP*) ([@B58]; [@B162]; [@B243]) and sudden cardiac death ([@B8]; [@B140]).

In the atria, remodeled biophysical properties of ionic channels ([@B14]) serve as substrates for AF, including accelerated repolarization, spatial and temporal AP instabilities, atrial refractoriness, early and delayed afterdepolarizations, ectopic firing, and single/multiple wave re-entrant mechanisms ([@B164]; [@B43]; [@B90]). Collectively these observations reveal potential targets for modulation by SFFA pathways.

Our recently published data suggest that IL-6 may be a critical inflammatory signaling molecule contributing to *TdP* in patients with rheumatoid arthritis ([@B125]). This finding identifies IL-6 as a potential therapeutic target in arrhythmias. In the following sections we highlight the modulation by IL-6 of *I~Na~*, *I~Ca,L~*, and *I~K~* currents critically involved in cardiac instabilities, that ultimately predisposes to lipotoxic cardiomyopathies.

Molecular Remodeling of Cardiac Ion Channels by Interleukin-6
=============================================================

Depolarizing Na Current (I*~Na~*)
---------------------------------

The modulation of *I~Na~* by IL-6 in cardiomyocytes is poorly understood; however, there is evidence for modulation of *I~Na~* by other pro-inflammatory cytokines in other cell systems. The pro-inflammatory cytokine IL-2, which is also associated with arrhythmias, ([@B188]) has been shown to increase the transcriptional levels of *SCN3B* leading to increased peak *I~Na~* density in Hela and HL-1 cells ([@B257]) and suggests a role for cytokine modulation of *I~Na~* functional expression in lipotoxicity. From the perspective of cardiac electrical remodeling, cytokine-mediated increases in *I~Na~* density will be expected to delay cardiac repolarization leading to prolongation of the QT interval. Future IL-6 studies in native atrial and ventricular cardiomyocytes and animal models of lipotoxicity are critical for fundamental insights into the functional consequence of IL-6 modulation of Na current in metabolic disease-related arrhythmias.

L-Type Ca Channels (I*~Ca,L~*)
------------------------------

Unlike *I~Na~*, IL-6 has been shown to regulate *I~Ca,L~*~,~ density. Hagiwara and others ([@B86]) demonstrated that acute (30 min) exposure to IL-6 and sIL-6R significantly increased *I~Ca,L~* density in mouse ventricular myocytes in line with a role for IL-6 in LQTS. In guinea pig ventricular myocytes acute (5 min) exposure to IL-6 had no effect on *I~Ca,L~*, but reversed the increased *I~Ca,L~* due to sympathetic stimulation with isoproterenol ([@B212]). By contrast, chronic (2 h) exposure to IL-6 alone had no effect on *I~Ca,L~* in adult rat ventricular myocytes ([@B253]) and therefore suggests temporal differences in IL-6 effects on channel function.

The Ca~v~1.2 channel subunit mediates *I~Ca,L~* current in both the atria and ventricles ([@B149]). Targeted deletion in mice has also demonstrated a functional role of the Ca~v~1.3 isoform in the pathogenesis of AF ([@B255]; [@B149]; [@B144]; [@B213]). Therefore, it will be interesting to investigate the differential regulation of Ca~v~1.2/Ca~v~1.3 by IL-6. With expression of Ca~v~1.3 only in the atria we may be able to identify new pathways that could be targeted for arrhythmias in patients with metabolic disorders, without off-target ventricular effects.

In agreement with this notion, we have recently found that Ca~v~1.3 expression is significantly downregulated in the atria of high-fat diet induced obese guinea pigs, while Ca~v~1.2 expression remained essentially unchanged (Ademuyiwa S Aromolaran, personal communication, Biophysical meeting 2018, San Diego, CA, United States). Although the role of Ca~v~1.3 in inflammation remains to be defined, the data suggests that Ca~v~1.3 expression and regulation could be participating in arrhythmogenic responses to lipotoxicity.

IL-6 studies in mice ventricular myocytes showed that acute exposure (10 min) to IL-6 and sIL-6R significantly increased intracellular Ca transients ([@B86]). This suggests a role for IL-6 in mediating arrhythmias through modulation of Ca-handling proteins. [@B253] showed that IL-6 induced negative inotropy, decreased postrest potentiation, as well as responsiveness to the ryanodine receptor (RyR) agonist caffeine in adult rat ventricular myocytes. Similarly, acute exposure to IL-6 produced decreased peak systolic intracellular Ca concentration (\[Ca^2+^\]~i~) and cell shortening leading to a negative ionotropic effect in guinea pig ventricular myocytes despite a lack of effect on *I~Ca,L~* ([@B212]). Human recombinant IL-6 significantly decreased peak systolic \[Ca^2+^\]~i~ and the amplitude of cell contraction in cultured chick embryo ventricular myocytes ([@B116]).

IL-6 may also directly regulate the activity of the sarcoplasmic reticulum Ca-ATPase (SERCA2). Previous reports showed that chronic (48 h) exposure of IL-6 caused a significant downregulation of SERCA2 gene and protein expression levels in cultured neonatal rat ventricular myocytes ([@B234]), while a 6 h exposure to IL-6 significantly decreased SERCA2 expression in cultured rat ventricular myocytes ([@B218]), consistent with impaired sarcoplasmic reticular (SR) function and propensity for arrhythmias.

The regulation by IL-6 of intracellular Ca dynamics through modulation of RyRs or the inositol triphosphate receptor (IP~3~R) is currently unknown. In the context of metabolic diseases, altered IL-6 mechanisms that decrease *I~Ca,L~* density, reduce intracellular Ca transients and impair cardiac contractility are also likely to promote supraventricular arrhythmias ([@B149]). To our knowledge, the underlying molecular mechanisms of IL-6 modulation of Ca~v~1.3 and Ca handling proteins in atrial myocytes are poorly understood and therefore warrants future studies. Nevertheless, the outcome of IL-6 studies in ventricular myocytes demonstrate that IL-6-mediated altered Ca handling proteins and subsequent inhibition of the SR function may contribute to impaired cardiac electrical activities in lipotoxicity.

The Delayed Rectifier K Current (I*~K~*)
----------------------------------------

Cardiac delayed rectifier K current, (or *I~K~*) contributes prominently to normal repolarization ([@B192]). The molecular partners of *I~K~*~,~ namely: *I~Kr~* and *I~Ks~* determine spatial and temporal activation and modulation of repolarization by *I~K~* ([@B193]; [@B15]). Thus, inactivation and/or downregulation of *I~K~*, either due to congenital mutations ([@B15]; [@B179]), or secondary to pathological disease states including diabetes ([@B59]), obesity ([@B171]), or drugs ([@B205]; [@B82]), will delay repolarization leading to LQTS. Recently, we demonstrated that both gating and trafficking defects underlie pathological decreases in *I~Kr~* and *I~Ks~* in heart ([@B15]; [@B179]).

A previous report by [@B235], showed TNF-α mediated depression of the human ether-à-go-go-related gene (or hERG) current density in human embryonic kidney (HEK293) cells. Further, TNF-α significantly reduced *I~Kr~* density and prolonged APD in canine ventricular myocytes, primarily though changes in reactive oxygen species ([@B235]). The effects of IL-6 on *I~Kr~* and *I~Ks~* currents as targets in its reported link to LQTS ([@B124]) is currently unknown. This is further complicated by a lack of clarity about the role of *I~K~* in AF. We have previously reported that the SFFA PA increased the densities of *I~Kr~* and *I~Ks~* currents in HEK293 cells and shortened atrial APD measured in adult guinea pig myocytes, in line with a role for *I~K~* in AF associated with metabolic disorders ([@B14]). Therefore, considering the idea that SFFAs activate macrophages and promote increased expression of IL-6 ([@B206]; Figure), our expectation is that *I~K~* may also be an important target for IL-6 modulation in AF pathogenesis in patients with metabolic disorders.

Future Directions
=================

Metabolic disorders and cardiac arrhythmias are interlinked epidemics with significant implications for public health. One explanation for the lack of progress may be due to incomplete understanding of cardiac electrical remodeling initiated through systemic and/or localized effects of SFFAs. Delineating unappreciated SFFA pathways could represent the basis for gaining new molecular mechanistic insights with implications for prevention of arrhythmias. This notion could be highlighted by the paucity of lipid studies that incorporate modulation by cytokines of cardiac ion channels, notably *I~K~* (*I~Kr~* and *I~Ks~*) a prominent repolarizing mechanism in heart.

We have focused on the pro/anti-inflammatory cytokine IL-6 as an important target for future investigation. This premise is based on our recent finding that pathological alterations in IL-6 may underlie arrhythmic risk in *TdP* patients ([@B124]). This study suggests the potential of anti-cytokine therapy as a novel treatment option. If proven, this may represent the missing link that we need to develop safer and more effective interventions, especially in *TdP* patients unresponsive to conventional treatment. The implication of altered IL-6/IL-6R signaling for arrhythmias in patients with metabolic disorders is currently not clear. In this context it will be interesting to: (1) know the differential expression of IL-6R in cardiomyocytes and in different subtypes of macrophages (2) investigate sources, spatial and temporal IL-6 concentrations, (3) distinguish between modifying enzymes and signaling pathways in specific cardiac regions, (4) understand the role of resident cardiac macrophages in the interplay between different cells in adipose tissues and how this may be affected in metabolic disorders.

Furthermore, the implications of production of distinct FFAs (SFFAs, monounsaturated FFAs, polyunsaturated FFAs) and cytokines (IL-6, TNF-α, IL-1β), from different sites (adipose tissue depot, macrophages, fibroblasts, lymphocytes, neutrophils, and cardiomyocytes), would be an interesting area of investigation. These pathways could be defined in animal models of inflammation and lipotoxicity, without confounding co-morbidities. Moreover, studies of individual disease phenotypes will allow us to define the specificity and linkage between multiple signaling pathways. This is especially important for precision or personalized medicine and development of targeted therapeutics for distinct arrhythmogenic mechanisms in patients.

It is noteworthy that the translational impact of mechanisms defined in animal models (mice, rats, guinea pig, rabbits, sheep), may be limited by differences in genetic background. Therefore, with more studies utilizing state-of-the art approaches, including human induced pluripotent stem (hiPSC)-derived cells (cardiomyocytes, macrophages, fibroblasts) and CRISPR-Cas9, to assess cardiac mechanisms of lipotoxicity, we may be able to better understand unique phenotypes in patients and improve our efforts to develop basic patient-specific interventions.

Conclusion
==========

Studies have revealed that there is a pathological link between dietary SFFAs and cardiac dysfunction. The increasing epidemic of metabolic disorders (dyslipidemia, obesity, T2D, insulin resistance, hyperglycemia), suggests that vulnerability to fatal arrhythmias and sudden cardiac death will remain high in patients. Despite advances in prognostic approaches and therapeutics, it is becoming increasingly clear that significant adjustments of existing approaches are needed. Pro-inflammatory signaling pathways are beginning to emerge as substrates for sustained lipotoxic events. While pathological inflammatory substrates may impair the ability of the heart to compensate for lipotoxic cardiomyopathies, the complexity of individual and synergistic effects of pro-inflammatory cells/cardiomyocytes limits a holistic understanding of this coupling. Importantly, the interplay with mechanisms (ion channel modulation) that lead to electrophysiological remodeling that support sustained and fatal arrhythmias are poorly understood. Therefore, if we understand the basic mechanisms involved, we may be able to prevent the abnormalities that eventually predispose patients to heart failure. With the increasing advent of promising tools ([@B74]; [@B90]), we are better equipped to identify novel therapeutic sites.

Author Contributions
====================

AA researched concepts, and edited and finalized the manuscript. MB finalized the manuscript. ASA obtained funding, conceived of, and wrote the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the American Heart Association (13SDG16850065 to ASA).

We thank Kelly A Aromolaran (Department of Medicine, Weill Cornell Medical College, New York, NY, United States) for comments and critical review of the manuscript.

AF

:   Atrial fibrillation

LQTS

:   Long QT syndrome

QT~c~

:   QT interval corrected for heart rate

AP

:   Action potential

APD

:   Action potential duration

*I~Kr~*

:   Rapidly activating delayed rectifier K current

*I~Ks~*

:   Slowly activating delayed rectifier K current

*I~Na~*

:   Voltage-gated Sodium current

*I~Ca~,~L~*

:   Voltage-gated L-type Ca current

*I~to~*

:   Fast transient outward K current

hERG

:   Human ether-á-go-go-related gene

HEK

:   Human Embryonic Kidney

FFAs

:   Free-fatty acids

SFFAs

:   Saturated Free-fatty acids

RyR

:   Ryanodine receptors

IP~3~R

:   Inositol trisphosphate

SR

:   Sarcoplasmic reticulum

SERCA

:   Sarcoplasmic endoplasmic reticulum Ca-ATPase pump

PA

:   Palmitic acid

OA

:   Oleic acid

T2D

:   Type 2 diabetes

IL-6

:   Interleukin-6

TLR

:   Toll-like receptor

TNF-α

:   Tumor necrosis factor alpha

NF-κB

:   Nuclear factor kappa-light-chain-enhancer of activated B cells

TdP

:   *Torsades de Pointes;* TIR Toll/interleukin-1 receptor

TRIF

:   TIR-domain-containing adapter-inducing interferon-β

TRAM

:   TRIF-related adapter molecule

TRAF

:   tumor necrosis factor receptor-associated factor

TAK

:   transforming growth factor β activated kinase

IRAK

:   interleukin-1 receptor-associated kinase

IKK

:   inhibitory kappa B alpha kinase

MD-2

:   myeloid differentiation protein-2

Ub

:   ubiquitin
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